Disease relevance of Detapac

• Weekly treatment with Ca-DTPA reduced the total Pu burden significantly, but these dogs also died with osteosarcoma between 1462 and 1783 days [1].
• Ca-DTPA-induced fetal death and malformation in mice [2].
• No pulmonary pathology was found from the single inhalation treatment with Ca-DTPA while only a slight, peripheral, histiocytosis was observed in the lungs of multiple-treated rats [3].
• Prompt treatment with 100 mumol Ca-DTPA/kg body weight diminished the skeletal 234Th content by about 70%; but when it was delayed by 6 h or 4 d, the 234Th content was reduced by only about 20% and 10%, respectively [4].
• Estimated toxicity of Ca-DTPA to the human fetus [5].

High impact information on Detapac

• Chelation therapy with calcium trisodium pentetate was more effective in enhancing the removal of americium-241 from the child than from the father [6].
• 59Fe release from alveolar macrophages ingested 59Fe-iron dextran--enhancement by combination of Ca-DTPA and macrophage activating substances [7].
• By extension, it seems likely that Ca-DTPA could damage human fetuses [2].
• Mated C57BL/Do female mice were given five daily injections of 720-2,880 mumol/kg Ca-DTPA during early, mid, or late gestation [2].
• On the influence of Ca-DTPA on delta-aminolevulinic acid dehydratase in rats [8].

Biological context of Detapac

• Female rats were given a single or 12 daily, 2-4 h, inhalation exposures to aerosols of 10, 20 and 40% Ca-DTPA and the lungs were examined at 21 and 42 days following the last exposure [3].

Analytical, diagnostic and therapeutic context of Detapac

• With a single early treatment (1.5 min after intravenous injection of 234Th), Zn-DTPA was clearly less effective than Ca-DTPA over the whole dose range (30 mumol/kg body weight-1000 mumol/kg body weight) tested [4].
• In rats red cell delta-aminolevulinic acid dehydratase is inhibited by Ca-DTPA only after treatment with toxic doses or with fractionated therapeutic doses [8].

References